| Bacillus subtilis |
4'-phosphopantetheinyl transferase ffp |
Potency |
35481.3 |
nM |
None |
| Drosophila |
Drosophila |
Activity |
67.0 |
% |
10.1038/nchembio.78 |
| Enterococcus faecium |
Enterococcus faecium |
MBC |
2000.0 |
uM |
10.1021/acs.jmedchem.5b02004 |
| Enterococcus faecium |
Enterococcus faecium |
MBC |
2000.0 |
uM |
10.1021/acs.jmedchem.7b01903 |
| Enterococcus faecium |
Enterococcus faecium |
MBEC |
2000.0 |
uM |
10.1021/acs.jmedchem.5b02004 |
| Enterococcus faecium |
Enterococcus faecium |
MBEC |
2000.0 |
uM |
10.1021/acs.jmedchem.7b01903 |
| Escherichia coli |
Escherichia coli |
Activity |
nan |
None |
10.1021/jm501844d |
| Escherichia coli |
Escherichia coli |
FC |
1.0 |
None |
10.1021/jm501844d |
| Escherichia coli |
Escherichia coli |
FC |
2.0 |
None |
10.1021/jm501844d |
| Homo sapiens |
Adenosine A1 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Adenosine A2a receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Adenosine A3 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Alpha-1a adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Alpha-2a adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Alpha-2b adrenergic receptor |
AC50 |
10000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Alpha-2c adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Arachidonate 15-lipoxygenase |
Potency |
25.1 |
nM |
None |
| Homo sapiens |
Ataxin-2 |
Potency |
11220.2 |
nM |
None |
| Homo sapiens |
ATP-dependent DNA helicase Q1 |
Potency |
1412.5 |
nM |
None |
| Homo sapiens |
Beta-1 adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Beta-2 adrenergic receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Bile acid receptor FXR |
Potency |
28183.8 |
nM |
None |
| Homo sapiens |
Bloom syndrome protein |
Potency |
1000.0 |
nM |
None |
| Homo sapiens |
Bradykinin B2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cannabinoid CB1 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cerebroside-sulfatase |
Potency |
37933.0 |
nM |
None |
| Homo sapiens |
Cholecystokinin A receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cholecystokinin B receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Cyclooxygenase-2 |
AC50 |
2400.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Delta opioid receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Dopamine D1 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Dopamine D1 receptor |
Potency |
20.6 |
nM |
None |
| Homo sapiens |
Dopamine D1 receptor |
Potency |
5804.5 |
nM |
None |
| Homo sapiens |
Dopamine D2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Dopamine D3 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Dopamine transporter |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
DU-145 |
Ratio |
0.8 |
None |
10.1016/j.bmcl.2018.05.025 |
| Homo sapiens |
ECa-109 cell line |
Activity |
0.2 |
% |
10.1016/j.ejmech.2020.112789 |
| Homo sapiens |
ECa-109 cell line |
Activity |
4.5 |
% |
10.1016/j.ejmech.2020.112789 |
| Homo sapiens |
ECa-109 cell line |
Activity |
4.8 |
% |
10.1016/j.ejmech.2020.112789 |
| Homo sapiens |
ECa-109 cell line |
Activity |
6.4 |
% |
10.1016/j.ejmech.2020.112789 |
| Homo sapiens |
Endothelin receptor ET-A |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Equilibrative nucleoside transporter 1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Estrogen receptor alpha |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Fibroblast |
Activity |
6.4 |
% |
10.1021/acs.jnatprod.9b01030 |
| Homo sapiens |
Fibroblast |
Activity |
18.5 |
% |
10.1021/acs.jnatprod.9b01030 |
| Homo sapiens |
Fibroblast |
Activity |
72.7 |
% |
10.1021/acs.jnatprod.9b01030 |
| Homo sapiens |
Fibroblast |
Activity |
74.1 |
% |
10.1021/acs.jnatprod.9b01030 |
| Homo sapiens |
Fibroblast |
Activity |
109.7 |
% |
10.1021/acs.jnatprod.9b01030 |
| Homo sapiens |
Flap endonuclease 1 |
Potency |
26679.5 |
nM |
None |
| Homo sapiens |
Geminin |
Potency |
259.3 |
nM |
None |
| Homo sapiens |
Ghrelin receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Glucocorticoid receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Glucocorticoid receptor |
Potency |
2.8 |
nM |
None |
| Homo sapiens |
Guanine nucleotide-binding protein G(s), subunit alpha |
Potency |
50118.7 |
nM |
None |
| Homo sapiens |
HaCaT |
Activity |
1.0 |
% |
10.1016/j.bmc.2017.03.069 |
| Homo sapiens |
HCT-116 |
Activity |
0.7 |
% |
10.1016/j.ejmech.2016.01.056 |
| Homo sapiens |
HCT-116 |
Activity |
1.1 |
% |
10.1021/acs.jnatprod.5b00743 |
| Homo sapiens |
HCT-116 |
Activity |
1.21 |
% |
10.1016/j.ejmech.2016.01.056 |
| Homo sapiens |
HCT-116 |
Activity |
1.75 |
% |
10.1016/j.ejmech.2016.01.056 |
| Homo sapiens |
HCT-116 |
Activity |
1.86 |
% |
10.1016/j.ejmech.2016.01.056 |
| Homo sapiens |
HCT-116 |
Activity |
4.9 |
% |
10.1021/acs.jnatprod.5b00743 |
| Homo sapiens |
HCT-116 |
Activity |
5.62 |
% |
10.1016/j.ejmech.2016.01.056 |
| Homo sapiens |
HCT-116 |
Activity |
6.0 |
% |
10.1021/acs.jnatprod.5b00743 |
| Homo sapiens |
HCT-116 |
Activity |
8.5 |
% |
10.1021/acs.jnatprod.5b00743 |
| Homo sapiens |
HCT-116 |
Activity |
85.6 |
% |
10.1021/acs.jnatprod.5b00743 |
| Homo sapiens |
HCT-116 |
Activity |
91.82 |
% |
10.1016/j.ejmech.2016.01.056 |
| Homo sapiens |
HEK293 |
Potency |
23099.9 |
nM |
None |
| Homo sapiens |
HepG2 |
Activity |
1.9 |
% |
10.1016/j.ejmech.2016.02.019 |
| Homo sapiens |
HepG2 |
Activity |
2.6 |
% |
10.1016/j.ejmech.2016.02.019 |
| Homo sapiens |
HepG2 |
Activity |
6.6 |
% |
10.1016/j.ejmech.2016.02.019 |
| Homo sapiens |
HepG2 |
Activity |
nan |
None |
10.1021/acs.jnatprod.9b00290 |
| Homo sapiens |
HERG |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Histamine H1 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Histamine H2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Histamine H3 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Histone deacetylase |
IC50 |
3160000.0 |
nM |
10.1016/j.bmcl.2015.11.045 |
| Homo sapiens |
Histone deacetylase 6 |
Inhibition |
-44.41 |
% |
10.6019/CHEMBL4808148 |
| Homo sapiens |
Histone deacetylase 6 |
Inhibition |
3.47 |
% |
10.6019/CHEMBL4808148 |
| Homo sapiens |
Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 |
Potency |
1412.5 |
nM |
None |
| Homo sapiens |
Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 |
Potency |
8436.8 |
nM |
None |
| Homo sapiens |
Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 |
Potency |
25118.9 |
nM |
None |
| Homo sapiens |
HL-60 |
Activity |
1.56 |
% |
10.1016/j.bmcl.2017.12.059 |
| Homo sapiens |
HL-60 |
Activity |
2.43 |
% |
10.1016/j.bmcl.2017.12.059 |
| Homo sapiens |
HL-60 |
Activity |
2.52 |
% |
10.1016/j.bmcl.2017.12.059 |
| Homo sapiens |
HL-60 |
Activity |
40.12 |
% |
10.1016/j.bmcl.2017.12.059 |
| Homo sapiens |
HL-60 |
Activity |
57.36 |
% |
10.1016/j.bmcl.2017.12.059 |
| Homo sapiens |
Homo sapiens |
DILI_Concern |
nan |
None |
10.1016/j.drudis.2016.02.015 |
| Homo sapiens |
Homo sapiens |
DILI_severity_class |
0.0 |
None |
10.1016/j.drudis.2016.02.015 |
| Homo sapiens |
Homo sapiens |
Drugexcretion |
30.0 |
% |
10.1039/C7MD00409E |
| Homo sapiens |
Homo sapiens |
F |
5.0 |
% |
10.1039/C7MD00409E |
| Homo sapiens |
Homo sapiens |
T1/2 |
5.6 |
hr |
10.1039/C7MD00409E |
| Homo sapiens |
Homo sapiens |
Untreated control |
88.0 |
% |
10.1021/jm980289j |
| Homo sapiens |
Homo sapiens |
Viscosity |
27.0 |
% |
10.1021/jm00145a011 |
| Homo sapiens |
Homo sapiens |
Viscosity |
31.0 |
% |
10.1021/jm00145a011 |
| Homo sapiens |
Homo sapiens |
Viscosity |
38.0 |
% |
10.1021/jm00145a011 |
| Homo sapiens |
HUVEC |
Activity |
nan |
None |
10.1016/j.ejmech.2012.07.016 |
| Homo sapiens |
HUVEC |
IC50 |
10000000.0 |
nM |
10.1039/C0MD00262C |
| Homo sapiens |
HUVEC |
Inhibition |
nan |
% |
10.1016/j.ejmech.2012.07.016 |
| Homo sapiens |
Kappa opioid receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
L02 |
Activity |
102.49 |
a.u. |
10.1016/j.bmcl.2017.07.028 |
| Homo sapiens |
L02 |
Activity |
nan |
None |
10.1016/j.bmcl.2017.07.028 |
| Homo sapiens |
L02 |
Activity |
nan |
None |
10.1039/C7MD00409E |
| Homo sapiens |
L02 |
Survival |
82.33 |
% |
10.1016/j.bmcl.2017.07.028 |
| Homo sapiens |
Lysine-specific demethylase 4A |
Potency |
89125.1 |
nM |
None |
| Homo sapiens |
Lysine-specific demethylase 4D-like |
Potency |
25118.9 |
nM |
None |
| Homo sapiens |
Melanocortin receptor 3 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Microtubule-associated protein tau |
Potency |
17782.8 |
nM |
None |
| Homo sapiens |
Microtubule-associated protein tau |
Potency |
31622.8 |
nM |
None |
| Homo sapiens |
Monoamine oxidase A |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Motilin receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Mu opioid receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Muscarinic acetylcholine receptor M1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Muscarinic acetylcholine receptor M2 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Muscarinic acetylcholine receptor M3 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Neuronal acetylcholine receptor protein alpha-4 subunit |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Neuropeptide Y receptor type 1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Neutrophil |
Inhibition |
nan |
% |
10.1021/acsmedchemlett.9b00142 |
| Homo sapiens |
Norepinephrine transporter |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Nuclear factor erythroid 2-related factor 2 |
Activity |
nan |
None |
10.1021/jm2002348 |
| Homo sapiens |
Nuclear factor NF-kappa-B p105 subunit |
Potency |
4466.8 |
nM |
None |
| Homo sapiens |
PC-3 |
Activity |
0.0 |
% |
10.1016/j.ejmech.2016.06.019 |
| Homo sapiens |
PC-3 |
Activity |
0.87 |
% |
10.1016/j.ejmech.2016.06.019 |
| Homo sapiens |
Peroxisome proliferator-activated receptor gamma |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Phosphodiesterase 3A |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Phosphodiesterase 4D |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Pregnane X receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Progesterone receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Regulator of G-protein signaling 4 |
Potency |
237.6 |
nM |
None |
| Homo sapiens |
Serotonin 1a (5-HT1a) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 2a (5-HT2a) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 2b (5-HT2b) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 2c (5-HT2c) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin 3a (5-HT3a) receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Serotonin transporter |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
SH-SY5Y |
Activity |
25.0 |
% |
10.1016/j.bmc.2010.11.053 |
| Homo sapiens |
SH-SY5Y |
Activity |
33.0 |
% |
10.1016/j.bmc.2010.11.040 |
| Homo sapiens |
SH-SY5Y |
Activity |
33.4 |
% |
10.1021/jm901902w |
| Homo sapiens |
SH-SY5Y |
Activity |
37.1 |
% |
10.1016/j.bmcl.2019.08.026 |
| Homo sapiens |
SH-SY5Y |
Activity |
37.1 |
% |
10.1016/j.bmcl.2020.127633 |
| Homo sapiens |
SH-SY5Y |
Activity |
37.1 |
% |
10.1016/j.ejmech.2019.111913 |
| Homo sapiens |
SH-SY5Y |
Activity |
53.8 |
% |
10.1016/j.ejmech.2021.113168 |
| Homo sapiens |
SH-SY5Y |
Activity |
63.1 |
% |
10.1016/j.bmc.2010.11.053 |
| Homo sapiens |
SH-SY5Y |
Activity |
67.6 |
% |
10.1016/j.ejmech.2021.113426 |
| Homo sapiens |
SH-SY5Y |
Activity |
68.2 |
% |
10.1016/j.ejmech.2021.113168 |
| Homo sapiens |
SH-SY5Y |
Activity |
72.5 |
% |
10.1016/j.ejmech.2021.113168 |
| Homo sapiens |
SH-SY5Y |
Activity |
79.3 |
% |
10.1016/j.ejmech.2021.113168 |
| Homo sapiens |
SH-SY5Y |
Activity |
82.27 |
% |
10.1016/j.ejmech.2021.113168 |
| Homo sapiens |
SH-SY5Y |
Activity |
83.59 |
% |
10.1016/j.ejmech.2021.113426 |
| Homo sapiens |
SH-SY5Y |
Activity |
84.3 |
% |
10.1016/j.bmcl.2020.127633 |
| Homo sapiens |
SH-SY5Y |
Activity |
84.3 |
% |
10.1016/j.bmcl.2021.128092 |
| Homo sapiens |
SH-SY5Y |
Activity |
84.73 |
% |
10.1016/j.ejmech.2021.113426 |
| Homo sapiens |
SH-SY5Y |
Activity |
89.01 |
% |
10.1016/j.ejmech.2021.113168 |
| Homo sapiens |
SH-SY5Y |
Activity |
89.2 |
% |
10.1016/j.bmcl.2014.11.068 |
| Homo sapiens |
SH-SY5Y |
Activity |
107.9 |
% |
10.1016/j.ejmech.2021.113168 |
| Homo sapiens |
SH-SY5Y |
Activity |
114.4 |
% |
10.1016/j.ejmech.2021.113168 |
| Homo sapiens |
SH-SY5Y |
Activity |
120.0 |
% |
10.1016/j.ejmech.2021.113168 |
| Homo sapiens |
SH-SY5Y |
Activity |
nan |
None |
10.1016/j.bmc.2011.07.033 |
| Homo sapiens |
SH-SY5Y |
Activity |
nan |
None |
10.1016/j.ejmech.2021.113168 |
| Homo sapiens |
SH-SY5Y |
EC50 |
1680000.0 |
nM |
10.1016/j.bmcl.2018.11.030 |
| Homo sapiens |
SH-SY5Y |
Inhibition |
35.0 |
% |
10.1016/j.ejmech.2014.03.042 |
| Homo sapiens |
SH-SY5Y |
Inhibition |
nan |
% |
10.1016/j.ejmech.2021.113168 |
| Homo sapiens |
Signal transducer and activator of transcription 3 |
Ratio |
1.0 |
None |
10.1016/j.bmcl.2018.05.025 |
| Homo sapiens |
Solute carrier family 22 member 1 |
Inhibition |
15.5 |
% |
10.1021/jm8003152 |
| Homo sapiens |
Solute carrier organic anion transporter family member 1B1 |
Inhibition |
82.21 |
% |
10.1124/mol.112.084152 |
| Homo sapiens |
Solute carrier organic anion transporter family member 1B3 |
Inhibition |
89.21 |
% |
10.1124/mol.112.084152 |
| Homo sapiens |
Survival motor neuron protein |
Potency |
1584.9 |
nM |
None |
| Homo sapiens |
Thrombopoietin |
Potency |
31622.8 |
nM |
None |
| Homo sapiens |
Thromboxane A2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Thyroid hormone receptor beta-1 |
Potency |
562.3 |
nM |
None |
| Homo sapiens |
Type-1 angiotensin II receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Ubiquitin carboxyl-terminal hydrolase 1 |
Potency |
39810.7 |
nM |
None |
| Homo sapiens |
Vasopressin V1a receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Vasopressin V2 receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Homo sapiens |
Vitamin D receptor |
Potency |
1122.0 |
nM |
None |
| Klebsiella pneumoniae |
Klebsiella pneumoniae |
Activity |
nan |
None |
10.1021/jm501844d |
| Klebsiella pneumoniae |
Klebsiella pneumoniae |
Activity |
nan |
None |
10.1128/aac.00893-06 |
| Klebsiella pneumoniae |
Klebsiella pneumoniae |
FC |
2.0 |
None |
10.1021/jm501844d |
| Mus musculus |
HT-22 |
Activity |
17.0 |
% |
10.1016/j.bmcl.2017.10.075 |
| Mus musculus |
HT-22 |
Activity |
nan |
None |
10.1016/j.bmcl.2017.10.075 |
| Mus musculus |
HT-22 |
Activity |
nan |
None |
10.1016/j.bmcl.2017.12.062 |
| Mus musculus |
HT-22 |
Activity |
nan |
None |
10.1016/j.bmcl.2018.11.042 |
| Mus musculus |
HT-22 |
Activity |
nan |
None |
10.1016/j.bmcl.2020.127058 |
| Mus musculus |
HT-22 |
EC50 |
700000.0 |
nM |
10.1021/acs.jnatprod.0c00756 |
| Mus musculus |
Mus musculus |
Activity |
20.0 |
% |
10.1021/acs.jnatprod.9b00523 |
| Mus musculus |
Mus musculus |
Activity |
nan |
None |
10.1021/acs.jnatprod.9b00523 |
| Mus musculus |
Mus musculus |
Activity |
nan |
None |
10.1021/np100240y |
| Mus musculus |
Mus musculus |
Deaths |
0.0 |
None |
10.1021/jm00347a001 |
| Mus musculus |
Mus musculus |
No. of animals |
0.0 |
None |
10.1021/jm00393a034 |
| Mus musculus |
Mus musculus |
No. of animals |
1.0 |
None |
10.1021/jm00393a034 |
| Mus musculus |
Mus musculus |
No. of animals |
3.0 |
None |
10.1021/jm00393a034 |
| Mus musculus |
Mus musculus |
No. of animals |
13.0 |
None |
10.1021/jm00393a034 |
| Mus musculus |
Mus musculus |
No. of animals with liver necrosis |
2.0 |
None |
10.1021/jm00347a001 |
| Mus musculus |
Mus musculus |
No. of animals with liver necrosis |
2.0 |
None |
10.1021/jm00371a006 |
| Mus musculus |
Mus musculus |
No. of animals with liver necrosis |
15.0 |
None |
10.1021/jm00347a001 |
| Mus musculus |
Mus musculus |
No. of animals with liver necrosis |
15.0 |
None |
10.1021/jm00371a006 |
| Mus musculus |
Mus musculus |
No. of survivors |
17.0 |
48h |
10.1021/jm00393a034 |
| Mus musculus |
Mus musculus |
Survival |
7.0 |
% |
10.1016/j.ejmech.2016.06.017 |
| Mus musculus |
Mus musculus |
Survival |
17.0 |
None |
10.1021/jm00371a006 |
| Mus musculus |
Mus musculus |
Survival |
94.0 |
% |
10.1021/jm00393a034 |
| Mus musculus |
RAW264.7 |
Inhibition |
nan |
% |
10.1016/j.bmc.2022.116627 |
| Pseudomonas aeruginosa |
Pseudomonas aeruginosa |
Activity |
nan |
None |
10.1021/jm501844d |
| Pseudomonas aeruginosa |
Pseudomonas aeruginosa |
FC |
4.0 |
None |
10.1021/jm501844d |
| Rattus norvegicus |
Androgen Receptor |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
Cyclooxygenase-1 |
AC50 |
890.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
GABA receptor alpha-1 subunit |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
Glutamate (NMDA) receptor subunit zeta 1 |
AC50 |
30000.0 |
nM |
10.1038/s41467-023-40064-9 |
| Rattus norvegicus |
H9c2 |
Activity |
20.0 |
% |
10.1021/jm301411g |
| Rattus norvegicus |
H9c2 |
Activity |
25.2 |
% |
10.1021/jm301411g |
| Rattus norvegicus |
H9c2 |
Activity |
nan |
None |
10.1021/acs.jnatprod.2c00924 |
| Rattus norvegicus |
H9c2 |
Activity |
nan |
None |
10.1021/jm301411g |
| Rattus norvegicus |
Hepatocyte |
EC50 |
105600.0 |
nM |
10.1016/j.ejmech.2018.01.011 |
| Rattus norvegicus |
Muscarinic acetylcholine receptor M1 |
Potency |
12589.3 |
nM |
None |
| Rattus norvegicus |
Nuclear receptor subfamily 1 group I member 2 |
Potency |
31622.8 |
nM |
None |
| Rattus norvegicus |
PC-12 |
Activity |
35.3 |
% |
10.1016/j.bmcl.2016.11.070 |
| Rattus norvegicus |
PC-12 |
Activity |
35.3 |
% |
10.1016/j.ejmech.2018.04.054 |
| Rattus norvegicus |
PC-12 |
Activity |
76.1 |
% |
10.1021/np3008182 |
| Rattus norvegicus |
PC-12 |
Activity |
nan |
None |
10.1074/jbc.m603712200 |
| Rattus norvegicus |
Peripheral myelin protein 22 |
Potency |
40533.4 |
nM |
None |
| Rattus norvegicus |
Rattus norvegicus |
Activity |
0.0 |
% |
10.1021/jm00210a019 |
| Rattus norvegicus |
Rattus norvegicus |
Activity |
23.5 |
% |
10.1128/aac.00001-09 |
| Rattus norvegicus |
Rattus norvegicus |
Activity |
23.6 |
% |
10.1128/aac.00001-09 |
| Rattus norvegicus |
Rattus norvegicus |
Activity |
27.4 |
% |
10.1128/aac.00001-09 |
| Rattus norvegicus |
Rattus norvegicus |
Activity |
nan |
None |
10.1016/j.bmcl.2016.08.043 |
| Rattus norvegicus |
Rattus norvegicus |
Activity |
nan |
None |
10.1021/jm00210a019 |
| Rattus norvegicus |
Rattus norvegicus |
[GSH] |
25.5 |
nM (10e6*cells)-1 |
10.1021/jm00393a034 |
| Rattus norvegicus |
Rattus norvegicus |
[GSH] |
45.8 |
nM (10e6*cells)-1 |
10.1021/jm00393a034 |
| Rattus norvegicus |
Rattus norvegicus |
GSH level |
nan |
None |
10.1021/jm00393a034 |
| Rattus norvegicus |
Solute carrier family 22 member 6 |
Activity |
nan |
None |
10.1124/mol.60.5.1091 |
| Rattus norvegicus |
Solute carrier family 22 member 6 |
Ki |
2000000.0 |
nM |
10.1124/mol.62.4.921 |
| Rattus norvegicus |
Thoracic aorta |
Activity |
nan |
None |
10.1021/jm101432z |
| Severe acute respiratory syndrome coronavirus 2 |
Replicase polyprotein 1ab |
Inhibition |
14.12 |
% |
10.6019/CHEMBL4495564 |
| Severe acute respiratory syndrome coronavirus 2 |
Replicase polyprotein 1ab |
Inhibition |
26.89 |
% |
10.6019/CHEMBL4495564 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
Hit score |
0.1287 |
None |
10.1101/2020.04.21.054387 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
Hit score |
0.2321 |
None |
10.1101/2020.04.21.054387 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
IC50 |
19952.62 |
nM |
10.6019/CHEMBL4651402 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
IC50 |
20000.0 |
nM |
10.6019/CHEMBL4651402 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
Inhibition |
-5.13 |
% |
10.21203/rs.3.rs-23951/v1 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
Inhibition |
0.16 |
% |
10.6019/CHEMBL4495565 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
Inhibition |
0.43 |
% |
10.6019/CHEMBL4495565 |
| Severe acute respiratory syndrome coronavirus 2 |
SARS-CoV-2 |
Inhibition index |
0.08157 |
None |
10.1101/2020.04.03.023846 |
| Staphylococcus aureus |
Staphylococcus aureus |
Activity |
nan |
None |
10.1128/aac.00893-06 |
| Staphylococcus aureus |
Staphylococcus aureus |
MBC |
2000.0 |
uM |
10.1021/acs.jmedchem.5b02004 |
| Staphylococcus aureus |
Staphylococcus aureus |
MBC |
2000.0 |
uM |
10.1021/acs.jmedchem.7b01903 |
| Staphylococcus aureus |
Staphylococcus aureus |
MBEC |
2000.0 |
uM |
10.1021/acs.jmedchem.5b02004 |
| Staphylococcus aureus |
Staphylococcus aureus |
MBEC |
2000.0 |
uM |
10.1021/acs.jmedchem.7b01903 |
| Staphylococcus aureus |
Staphylococcus aureus |
Survival |
51.3 |
% |
10.1021/acs.jmedchem.7b01300 |
| Staphylococcus aureus |
Staphylococcus aureus |
Survival |
57.33 |
% |
10.1016/j.ejmech.2017.12.090 |
| Staphylococcus aureus |
Staphylococcus aureus |
Survival |
60.7 |
% |
10.1021/acs.jmedchem.7b00949 |
| Staphylococcus aureus (strain Mu50 / ATCC 700699) |
4,4'-diapophytoene desaturase (4,4'-diaponeurosporene-forming) |
Survival |
24.3 |
% |
10.1021/acs.jmedchem.7b00949 |
| Staphylococcus aureus (strain Mu50 / ATCC 700699) |
4,4'-diapophytoene desaturase (4,4'-diaponeurosporene-forming) |
Survival |
53.0 |
% |
10.1021/acs.jmedchem.7b01300 |
| Staphylococcus aureus (strain MW2) |
Dehydrosqualene desaturase |
Survival |
54.3 |
% |
10.1021/acs.jmedchem.7b01300 |
| Staphylococcus aureus (strain USA300) |
4,4'-diapophytoene desaturase (4,4'-diaponeurosporene-forming) |
Survival |
52.0 |
% |
10.1021/acs.jmedchem.7b01300 |
| Staphylococcus epidermidis |
Staphylococcus epidermidis |
Activity |
nan |
None |
10.1128/aac.00893-06 |
| Staphylococcus epidermidis |
Staphylococcus epidermidis |
MBC |
2000.0 |
uM |
10.1021/acs.jmedchem.5b02004 |
| Staphylococcus epidermidis |
Staphylococcus epidermidis |
MBC |
2000.0 |
uM |
10.1021/acs.jmedchem.7b01903 |
| Staphylococcus epidermidis |
Staphylococcus epidermidis |
MBEC |
2000.0 |
uM |
10.1021/acs.jmedchem.5b02004 |
| Staphylococcus epidermidis |
Staphylococcus epidermidis |
MBEC |
2000.0 |
uM |
10.1021/acs.jmedchem.7b01903 |
| Sus scrofa |
LLC-PK1 |
Activity |
89.4 |
% |
10.1016/j.bmcl.2021.128256 |
| Sus scrofa |
LLC-PK1 |
Activity |
nan |
None |
10.1016/j.bmcl.2021.128256 |
| Trypanosoma brucei |
6-phospho-1-fructokinase |
Potency |
26854.5 |
nM |
None |
| None |
ADMET |
CL |
3.1 |
mL.min-1.kg-1 |
10.1124/dmd.108.020479 |
| None |
ADMET |
GSH |
200.0 |
None |
10.1016/s0960-894x(01)00171-8 |
| None |
ADMET |
MRT |
3.0 |
hr |
10.1124/dmd.108.020479 |
| None |
ADMET |
Papp |
0.61 |
10'-6 cm/s |
10.1039/C7MD00409E |
| None |
ADMET |
Papp |
1.09 |
10'-6 cm/s |
10.1039/C7MD00409E |
| None |
ADMET |
T1/2 |
5.5 |
hr |
10.1124/dmd.108.020479 |
| None |
ADMET |
Vdss |
0.55 |
L.kg-1 |
10.1124/dmd.108.020479 |
| None |
Hepatotoxicity |
Alkaline Phosphatase Increase - Activity Score |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
Alkaline Phosphatase Increase - Index Value |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
Alkaline Phosphatase Increase - Number of Reports |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
Composite Activity - Active |
1.0 |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
Composite Activity - Marginal |
0.0 |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
Composite Activity - Score |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
GGT Increase - Activity Score |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
GGT Increase - Index Value |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
GGT Increase - Number of Reports |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
Hepatotoxicity |
nan |
None |
10.1021/tx1000865 |
| None |
Hepatotoxicity |
Hepatotoxicity |
nan |
None |
10.1021/tx900326k |
| None |
Hepatotoxicity |
Hepatotoxicity |
nan |
None |
10.1124/dmd.110.035113 |
| None |
Hepatotoxicity |
HepSE_bilirubinemia |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_cholecystitis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_cholelithiasis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_cirrhosis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_Combined Scores |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_elevated liver function tests |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_hepatic failure |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_hepatic necrosis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_hepatitis |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_hepatomegaly |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_jaundice |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_liver disease |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_liver fatty |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
HepSE_liver function tests abnormal |
0.0 |
None |
10.1371/journal.pcbi.1002310 |
| None |
Hepatotoxicity |
LDH Increase - Activity Score |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
LDH Increase - Index Value |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
LDH Increase - Number of Reports |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
SGOT Increase - Activity Score |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
SGOT Increase - Index Value |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
SGOT Increase - Number of Reports |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
SGPT Increase - Activity Score |
nan |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
SGPT Increase - Index Value |
4.8 |
None |
10.2174/1570163043334794 |
| None |
Hepatotoxicity |
SGPT Increase - Number of Reports |
4.0 |
None |
10.2174/1570163043334794 |
| None |
Molecular identity unknown |
Activity |
2.66 |
% |
10.1016/j.bmc.2011.05.054 |
| None |
Molecular identity unknown |
Activity |
12.33 |
% |
10.1021/np4003355 |
| None |
Molecular identity unknown |
Activity |
20.18 |
% |
10.1016/j.bmc.2011.05.054 |
| None |
Molecular identity unknown |
Activity |
29.18 |
% |
10.1016/j.bmc.2011.05.054 |
| None |
Molecular identity unknown |
Activity |
44.41 |
% |
10.1016/j.bmc.2011.05.054 |
| None |
Molecular identity unknown |
Activity |
55.78 |
% |
10.1021/np4003355 |
| None |
Molecular identity unknown |
Activity |
nan |
None |
10.1016/j.bmcl.2013.01.038 |
| None |
NON-PROTEIN TARGET |
Activity |
2.4 |
None |
10.1016/j.bmc.2010.01.057 |
| None |
NON-PROTEIN TARGET |
Activity |
17.2 |
% |
10.1016/j.ejmech.2015.08.057 |
| None |
NON-PROTEIN TARGET |
Activity |
53.7 |
% |
10.1016/j.ejmech.2015.08.057 |
| None |
NON-PROTEIN TARGET |
Activity |
96.3 |
% |
10.1016/j.bmc.2011.07.021 |
| None |
NON-PROTEIN TARGET |
Fu |
0.17 |
None |
10.1124/dmd.108.020479 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (acute) |
0.0 |
% |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (animal toxicity known) |
nan |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (benign tumour) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (granulomatous hepatitis) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (mechanism) |
nan |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (moderate) |
0.0 |
% |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (moderate) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
Hepatotoxicity (time to onset) |
nan |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
NON-PROTEIN TARGET |
IC50 |
28800000.0 |
nM |
10.1021/jm2001663 |
| None |
NON-PROTEIN TARGET |
IC50 |
29900000.0 |
nM |
10.1021/jm2001663 |
| None |
No relevant target |
EC50 |
27900.0 |
nM |
10.1016/j.ejmech.2020.112593 |
| None |
No relevant target |
EC50 |
28000.0 |
nM |
10.1016/j.ejmech.2016.12.048 |
| None |
No relevant target |
IC50 |
85000.0 |
nM |
10.1016/j.bmcl.2017.12.049 |
| None |
No relevant target |
K |
0.5 |
10'3/M/s |
10.1016/j.ejmech.2017.03.061 |
| None |
No relevant target |
K |
13.6 |
10'9/M/s |
10.1016/j.ejmech.2017.03.061 |
| None |
No relevant target |
K |
19.3 |
10'5/M/s |
10.1016/j.ejmech.2017.03.061 |
| None |
No relevant target |
K |
20.5 |
10'7/M/s |
10.1016/j.ejmech.2017.03.061 |
| None |
No relevant target |
-log(solubility) |
4.61 |
None |
10.1016/j.bmcl.2015.02.013 |
| None |
No relevant target |
-log(solubility) |
4.91 |
None |
10.1016/j.bmcl.2015.02.013 |
| None |
No relevant target |
-log(solubility) |
5.21 |
None |
10.1016/j.bmcl.2015.02.013 |
| None |
No relevant target |
-log(solubility) |
nan |
None |
10.1016/j.bmcl.2015.02.013 |
| None |
No relevant target |
pKa |
9.52 |
None |
10.1016/s0960-894x(00)00688-0 |
| None |
No relevant target |
T1/2 |
10.9 |
hr |
10.1021/jm00205a023 |
| None |
No relevant target |
T1/2 |
12.8 |
hr |
10.1021/jm00205a023 |
| None |
Unchecked |
Ac50 |
0.7079 |
uM |
None |
| None |
Unchecked |
Ac50 |
0.7943 |
uM |
None |
| None |
Unchecked |
Ac50 |
11.22 |
uM |
None |
| None |
Unchecked |
Ac50 |
39.81 |
uM |
None |
| None |
Unchecked |
Ac50 |
44.67 |
uM |
None |
| None |
Unchecked |
AC50 |
707.9 |
nM |
None |
| None |
Unchecked |
AC50 |
800.0 |
nM |
None |
| None |
Unchecked |
AC50 |
11220.2 |
nM |
None |
| None |
Unchecked |
AC50 |
39810.7 |
nM |
None |
| None |
Unchecked |
AC50 |
44668.4 |
nM |
None |
| None |
Unchecked |
Activity |
2.35 |
% |
10.1016/j.bmcl.2016.08.043 |
| None |
Unchecked |
Activity |
10.12 |
% |
10.1016/j.bmcl.2016.08.043 |
| None |
Unchecked |
Activity |
26.1 |
% |
10.1016/j.bmc.2011.05.054 |
| None |
Unchecked |
Activity |
62.6 |
% |
10.1039/C9MD00211A |
| None |
Unchecked |
Activity |
66.4 |
% |
10.1016/j.ejmech.2021.113168 |
| None |
Unchecked |
Activity |
69.5 |
% |
10.1039/C9MD00211A |
| None |
Unchecked |
Activity |
69.7 |
% |
10.1016/j.ejmech.2021.113168 |
| None |
Unchecked |
Activity |
79.1 |
% |
10.1039/C9MD00211A |
| None |
Unchecked |
Activity |
nan |
None |
10.1016/j.bmc.2011.07.021 |
| None |
Unchecked |
Activity |
nan |
None |
10.1016/j.bmcl.2018.02.028 |
| None |
Unchecked |
Delta Tm |
1.1 |
degrees C |
10.1021/jm501844d |
| None |
Unchecked |
FC |
0.76 |
None |
10.1016/j.ejmech.2021.113168 |
| None |
Unchecked |
FC |
4.0 |
None |
10.1021/acs.jmedchem.6b00228 |
| None |
Unchecked |
Hepatotoxicity (acute) |
1.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (association with vascular disease) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (choleostasis) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (chronic liver disease) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (cirrhosis) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (comment) |
nan |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (cytolytic) |
1.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (malignant tumour) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (severe hepatitis) |
0.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (steatosis) |
1.0 |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
Hepatotoxicity (successful reintroduction) |
nan |
None |
10.1016/s0399-8320(04)95062-2 |
| None |
Unchecked |
IC50 |
20700.0 |
nM |
10.1021/jm501844d |
| None |
Unchecked |
IC50 |
31000.0 |
nM |
10.1016/j.bmcl.2007.02.008 |
| None |
Unchecked |
IC50 |
100000000.0 |
nM |
10.1021/jm00205a023 |
| None |
Unchecked |
IC50 |
nan |
None |
10.1021/jm501844d |
| None |
Unchecked |
Inhibition |
nan |
% |
10.1021/acs.jmedchem.6b00228 |
| None |
Unchecked |
Inhibition |
nan |
% |
10.1038/nchembio821 |
| None |
Unchecked |
Inhibition |
nan |
% |
10.1038/nchembio873 |
| None |
Unchecked |
Potency |
2310.9 |
nM |
None |
| None |
Unchecked |
Potency |
7943.3 |
nM |
None |
| None |
Unchecked |
Potency |
10000.0 |
nM |
None |
| None |
Unchecked |
Potency |
23099.9 |
nM |
None |
| None |
Unchecked |
Ratio IC50 |
1.04 |
None |
10.1021/jm2001663 |
| None |
Unchecked |
Survival |
54.7 |
% |
10.1021/acs.jmedchem.7b00949 |
| None |
Unchecked |
Survival |
57.0 |
% |
10.1021/acs.jmedchem.7b00949 |